Highest-materiality recent filing
CEO Geordan Pursglove: 350,000 options cancelled, 350,000 RSUs awarded; CFO Peter Stazzone: 50,000 each.
Lixte restructures Liora acquisition; issues 700k shares, $440k cash, Bitcoin/Ethereum for 80% stake
Amended Share Exchange consolidates prior transactions; Lixte acquires 800 of 1,000 Liora shares (80%).
Lixte expands ovarian cancer trial to 42 patients; expects initial data in H1 2026
Amendment No.2 to collaborative study doubles enrollment from 21 to 42 patients for LB-100 + dostarlimab trial in ovarian clear cell carcinoma.
Lixte Biotechnology raises $4.3M in registered direct offering; terminates royalty agreement
Gross proceeds ~$4.3M from 1,051,342 Common Units at $4.09/unit; each unit includes one share (or Pre-Funded Warrant) and one Common Warrant (exercise $3.96, 60-month term).
Consideration: 2,700 Series C Preferred shares (convertible to 2.7M common), 10.56 BTC + 300 ETH, $440K cash, and 10% royalty on net revenue up to $45M.
LIXTE makes $2.6M initial cryptocurrency purchase to diversify treasury
Purchased 10.5 Bitcoin and 300 Ethereum for total of $2.6 million.
Lixte appoints new CFO, two board members; relocates HQ to Boca Raton
Rene Bernards, Regina Brown, Bas van der Baan resigned from Board; CFO Robert Weingarten resigned; all departures amicable.
LIXTE raises $6.5M, adds new CEO/board members, regains Nasdaq compliance
Completed two financings raising $6.5M gross ($5M private placement + $1.5M registered direct); proceeds for working capital.
Lixte appoints two new independent directors; CMO resigns effective July 31
Board adds Jason Sawyer and Dr. Michael Holloway as independent directors, designated by Series B Preferred Stock holders.
LIXTE Biotechnology regains Nasdaq equity compliance after $6.5M capital raise
Received Nasdaq hearings panel notice of compliance with Listing Rule 5550(b)(1) requiring min $2.5M equity.
Nature publication validates LIXTE's PP2A approach in ovarian and colorectal cancers
Nature study: OCCC patients with PPP2R1A mutations had significantly better overall survival on immunotherapy.
Lixte Biotechnology closes $1.5M registered direct offering of common stock and pre-funded warrants
Closed registered direct offering of 974,026 shares (or pre-funded warrants) at $1.54 per share for gross proceeds of ~$1.5M.
Lixte closes $5.0M private placement of common stock, preferred and warrants
Gross proceeds of $5.0M; $4.0M received at closing July 2, 2025; $1.0M due upon SEC registration effectiveness.
Lixte appoints Geordan Pursglove as CEO, contingent on Nasdaq financing by July 3
Geordan Pursglove appointed CEO and Chairman; Bastiaan van der Baan resigns as CEO, remains President and CSO.
Bastiaan van der Baan resigned as Chairman of the Board of Directors and Chief Executive Officer
effective June 16, 2025, Geordan Pursglove was appointed as the Company’s Chairman of the Board of Directors and Chief Executive Officer,
Max materiality 0.85 · Median 0.60 · Most common event other_material